Inovio Pharmaceuticals (NASDAQ:INO) Given New $3.00 Price Target at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO) had its price target reduced by HC Wainwright from $5.00 to $3.00 in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also issued reports on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 target price on shares of Inovio Pharmaceuticals in a research report on Friday. Oppenheimer dropped their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. Finally, Royal Bank of Canada dropped their target price on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $12.40.

Inovio Pharmaceuticals Trading Down 4.0 %

Shares of INO stock opened at $1.90 on Monday. Inovio Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $14.75. The firm’s fifty day simple moving average is $3.42 and its 200 day simple moving average is $6.09. The firm has a market capitalization of $49.59 million, a P/E ratio of -0.91 and a beta of 0.84.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of INO. Geode Capital Management LLC boosted its stake in shares of Inovio Pharmaceuticals by 6.7% in the 3rd quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock valued at $3,594,000 after purchasing an additional 38,833 shares in the last quarter. Barclays PLC lifted its position in Inovio Pharmaceuticals by 282.6% during the 3rd quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 25,116 shares in the last quarter. FMR LLC lifted its position in Inovio Pharmaceuticals by 370.1% during the 3rd quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 21,462 shares in the last quarter. State Street Corp lifted its position in Inovio Pharmaceuticals by 11.7% during the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after buying an additional 51,414 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Inovio Pharmaceuticals by 62.2% during the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 12,100 shares in the last quarter. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.